Drug class linked to worse outcomes after transplant
(HealthDay)—Kidney transplant patients who receive mammalian target of rapamycin (mTOR) inhibitors after transplant have a greater probability of death or transplant failure than patients receiving calcineurin inhibitors, ...
Oct 14, 2012
0
0